Reduced creatine kinase release with statin use at the time of myocardial infarction

International Journal of Cardiology

Volumn 96, Issue 3, 2004, Pages 461-466

  Bybee, Kevin A ^a   Kopecky, Stephen L ^a   Williams, Brent A ^b   Murphy, Joseph G ^a   Wright, R Scott ^a  

^a MAYO CLINIC   (United States)

^b Division of Biostatistics   (United States)

Author keywords

Creatine kinase; HMG CoA reductase inhibitors; Myocardial infarction; Statins

Indexed keywords

CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY CARE UNIT; CYTOKINE RELEASE; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; REDUCTION; STATISTICAL ANALYSIS;

AGED; CREATINE KINASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 4143075926     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2004.02.016     Document Type: Article

References (38)

1. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels (CARE). N. Engl. J. Med. 335(14):1996;1001-1009
2. Scandinavian Simvastatin Study Group Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389
3. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339:1998;1349-1357
4. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary artery disease with pravastatin in men with hypercholesterolemia: the West of Scotland Coronary Prevention Study. N. Engl. J. Med. 333:1995;1301-1307
5. Downs J.R., et al. For the AFCAPS/TexCAPS Research Group Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of the AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622
6. Heart Protection Study Collaborative Group MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360(9326):2002;7-22
7. Albert M.A., Danielson E., Rifai N., Ridker P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 286(1):2001;64-70
8. Ridker P.M., et al. For the cholesterol and recurrent events (CARE) investigators Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98:1998;839-844
9. Bustos C., Hernandez-Presa M., Ortego M., Tunon J., Ortega L., Perez F., et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J. Am. Coll. Cardiol. 32:1998;2057-2064
10. Lacoste L., Lam J.Y.T. Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients. J. Am. Coll. Cardiol. 27:1996;413A
11. Notarbartolo A., Davi G., Averna M., Barbagallo C.M., Ganci A., Giammarresi C., et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler. Thromb Vasc. Biol. 15:1995;247-251
12. Avellone G., DiGarbo V., Cordova R., Raneli G., De Simone R., Bompiani G. Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIB hyperlipoproteinemia. Curr. Ther. Res., Clin. Exp. 55:1994;1335-1344
13. Beigel Y., Fuchs J., Snir M., Green P., Lurie Y., Djaldetti M. Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology. J. Clin. Pharmacol. 31:1991;512-517
14. Dupuis J., Tardif J.-C., Cernacek P., Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) Trial. JAMA. 279:1998;1647-1650
15. O'Driscoll G., Green D., Taylor R. Simvastatin, an HMG-coenzyme a reductase inhibitor, improves endothelial function within 1 month. Circulation. 95:1997;1126-1131
16. Laufs U., La Fata V., Plutzky J., Liao K. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation. 97:1998;1129-1135
17. Tiefenbacher C., Kapitza J., Dietz V., Lee C.-H., Niroomand F. Reduction of myocardial infarct size by fluvastatin. Am. J. Physiol.: Heart Circ. Physiol. 285:2003;H59-H64
18. Ueda Y., Kitakaze M., Komamura K., Minamino T., Asanuma H., Sato H., et al. Pravastatin restores the infarct size-limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarction. J. Am. Coll. Cardiol. 34(7):1999;2120-2125
19. Di Napoli P., Taccardi A., Grilli A., Spina R., Felaco M., Barsotti A., et al. Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc. Res. 51:2001;283-293
20. Lefer A.M., Campbell B.A., Shin Y.-K., Scalia R., Hayward R., Lefer D.J. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation. 100:1999;178-184
21. Lefer D.J., Scalia R., Jones S.P., Sharp B.R., Hoffmeyer M.R., Farvid A.R., et al. HMG-CoA reductase inhibition protects the diabetic myocardium from ischmia-reperfusion injury. FASEB J. 15:2001;1454-1456
22. Herrmann J., Lerman A., Baumgart D., Volbracht L., Schulz R., von Birgelen C., et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation. 106(17):2002;2180-2183
23. Bybee K.A., Wright R.S., Williams B., Murphy J., Holmes D., Kopecky S. Effect of concomitant or very early statin administration on in-hospital mortality and re-infarction rates in patients with acute myocardial infarction. Am. J. Cardiol. 87:2001;771-774
24. Stenestrand U., Wallentin L., Swedish Register of Cardiac Intensive Care (RIKS-HIA) Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 285(4):2001;430-436
25. Aronow H.D., Topol E.J., Roe M.T., Houghtaling P.L., Wolski K.E., Lincoff A.M., et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 357(9262):2001;1063-1068
26. Bybee K.A., Wright R.S., Williams B., Kopecky S. Differential benefit from early treatment with a statin agent after non-ST elevation myocardial infarction compared with ST elevation myocardial infarction. Circulation. 102(18 supplement):2000 (October);II.614
27. Schiele R., Gitt A.K., Heer T., et al. Early statin use in acute myocardial infarction is associated with a reduced hospital mortality: results of the Mitra-2 [abstract]. Circulation. 102(Suppl. 2):2000;II-435. [Abstract 2117]
28. Hamm C.W., Heeschen C., Boehm M., White H.D. Role of statins in patients with acute coronary syndromes [abstract]. Circulation. 102(Suppl. 2):2000;II-435. [Abstract 2118]
29. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL Study. JAMA. 285(13):2001;1711-1718
30. Maruyama J., Onodera S., Imura S., Marutani Y., Takahori T., Nasuhara K. Infarct size in patients with acute myocardial infarction estimated by emission computed tomography with technitium-99 m pyrophosphate: relation to creatine kinase release. J. Cardiol. 16(3):1986;545-553
31. Kahn J.C., Gueret P., Baudet M., Rocha P., Bardet J., Bourdarias J.P. Clinical assessment of infarct size by serial determination of serum creatine phosphokinase. Eur. J. Cardiol. 9(1):1979;21-37
32. Wright R.S., Murphy J.G., Bybee K.A., Kopecky S.L., LaBlanche J.M. Statin lipid lowering therapy in patients with acute myocardial infarction and unstable angina: a practical review of efficacy and mechanism of benefit. Mayo Clin. Proc. 77(10):2002;1085-1092
33. Bybee K.A., Wright R.S., Kopecky S.L. Effect of early statin therapy after acute coronary syndromes: a concise review of the recent data. Cardiol. Rev. 10(5):2002;301-305
34. Davies M.J. The pathophysiology of acute coronary syndromes. Heart. 83:2000;361-366
35. Entman M.L., Michael L., Rossen R.D., Dreyer W.J., Anderson D.C., Taylor A.A., et al. Inflammation in the course of early myocardial ischemia. FASEB J. 5:1991;2529-2537
36. Forman M.B., Kolodgie F.D., Jenkins M., Virami R. Endothelial and myocardial injury during ischemia and reperfusion: pathogenesis and therapeutic implications. J. Am. Coll. Cardiol. 21:1993;1245-1253
37. Thompson P.L., Fletcher E.E., Katavatis V. Enzymatic indices of myocardial necrosis: influence on short- and long-term prognosis after myocardial infarction. Circulation. 59(1):1979;113-119
38. Savonitto S., Granger C., Ardissino D., Gardner L., Cavallini C., Galvani M., et al. The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. J. Am. Coll. Cardiol. 39:2002;22-29